论文部分内容阅读
目的评价药物治疗慢性充血性心力衰竭(CHF)中尿钠肽(BNP)检测的意义。方法选择CHF、心功能Ⅱ～Ⅲ级(NYHA分级)患者41例,年龄43～87岁,平均(63±12)岁。检测BNP后,将其分为常规治疗组21例(血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂+利尿剂+地高辛),酒石酸美托洛尔组20例(常规治疗+酒石酸美托洛尔),并在治疗3个月后重复检测BNP。BNP采用荧光免疫法测定。结果心力衰竭得到有效治疗后,两组BNP均显著下降(P<0.01),但两组治疗3个月后的BNP值比较,差异有统计学意义(P<0.01),说明酒石酸美托洛尔组优于常规治疗组。结论BNP检测在评价慢性充血性心力衰竭的药物疗效中具有重要的应用价值。
Objective To evaluate the significance of detecting urinary natriuretic peptide (BNP) in drug therapy for chronic congestive heart failure (CHF). Methods Forty-one patients with CHF of grade Ⅱ ~ Ⅲ (NYHA classification) were aged 43 to 87 years (mean, 63 ± 12). After the detection of BNP, it was divided into routine treatment group 21 cases (angiotensin converting enzyme inhibitor or angiotensin receptor blocker diuretic + digoxin), metoprolol tartrate group 20 cases (conventional treatment + Metoprolol tartrate) and repeated BNP testing after 3 months of treatment. BNP was measured by fluorescence immunoassay. Results BNP was significantly decreased in both groups after effective treatment of heart failure (P <0.01), but the difference was statistically significant (P <0.01) between the two groups after 3 months of treatment, indicating that metoprolol tartrate Group than conventional treatment group. Conclusion BNP test has important value in evaluating the curative effect of chronic congestive heart failure.